Development of new tharapy and search for new cell death mechanism in hematologic malignancies

点击翻译按钮获取中文摘要

We have done the following three projects to develop new therapies for chemo-resisitant hematologic malignancies. (1) To search new cell death mechanism of refractory leukemia in vivo (2) To search new prognostic factors in refractory leukemia (3) Analyze function of cells in minimal residual disease (MRD) of AML. (1) We detected autophagic cells in bone marrow, liver, spleen and craniospinal system of NOG mouse transplanted Ph1 ALL leukemic cells after treatment of dasatinib. (2) We analysed KIT mutations in AML-05 samples. Event free survivals are poor and relapse rates are high in KIT mutation positive patients. (3) We detected CD56 expression in CD34+CD33+ precursor cells only in Down syndrome patients and not in non-Down syndrome patients. We have to be carefully analyse MRD detection especially in Down syndrome patients.